Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02675556 · ClinicalTrials.gov registry record · Phase 1
Allogeneic Human Mesenchymal Stem Cells (hMSCs) Infusion in Patients With Treatment Resistant Depression
A Phase 1 study, sponsored by Joshua M Hare.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT02675556 is a Phase 1 study that was terminated before completion, run by Joshua M Hare. The registered enrollment target is 1 participants.
The verdict
NCT02675556, a Phase 1 study, was terminated before completion, sponsored by Joshua M Hare.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This study is intended to evaluate the safety and potential efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion versus placebo in patients with Treatment Resistant Depression.
Interventions
- DRUG Placebo
- DRUG Allo-hMSCs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2017-10-31 |
| Est. Completion | 2019-03-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02675556
The ClinicalTrials.gov registry entry for NCT02675556 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Joshua M Hare, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02675556 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02675556 about?
NCT02675556 is a clinical study titled "Allogeneic Human Mesenchymal Stem Cells (hMSCs) Infusion in Patients With Treatment Resistant Depression". This study is intended to evaluate the safety and potential efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion versus placebo in patients with Treatment Resistant Depression.
What is the current status of trial NCT02675556?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2017-10-31. Estimated completion is 2019-03-26.
What interventions are being tested in trial NCT02675556?
The interventions under investigation include: Placebo (DRUG), Allo-hMSCs (DRUG).
Who is sponsoring clinical trial NCT02675556?
This trial is sponsored by Joshua M Hare, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.